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Abstract
Background: Health policy in the UK has rapidly diverged since devolution in 1999. However,
there is relatively little comparative data available to examine the impact of this natural experiment
in the four UK countries. The Quality and Outcomes Framework of the 2004 General Medical
Services Contract provides a new and potentially rich source of comparable clinical quality data
through which we compare quality of primary medical care for coronary heart disease (CHD),
stroke, hypertension and diabetes across the four UK countries.
Methods: A cross-sectional analysis was undertaken involving 10,064 general practices in England,
Scotland, Wales and Northern Ireland. The main outcome measures were prevalence rates for
CHD, stroke, hypertension and diabetes. Achievement on 14 simple process, 3 complex process,
9 intermediate outcome and 5 treatment indicators for the four clinical areas.
Results: Prevalence varies by up to 28% between the four UK countries, which is not reflected in
resource distribution between countries, and penalises practices in the high prevalence countries
(Wales and Scotland). Differences in simple process measures across countries are small. Larger
differences are found for complex process, intermediate outcome and treatment measures, most
notably for Wales, which has consistently lower quality of care. Scotland has generally higher quality
than England and Northern Ireland is most consistently the highest quality.
Conclusion: Previously identified weaknesses in Wales related to waiting times appear to reflect
a more general quality problem within NHS Wales. Identifying explanations for the observed
differences is limited by the lack of comparable data on practice resources and organisation.
Maximising the value of cross-jurisdictional comparisons of the ongoing natural experiment of
health policy divergence within the UK requires more detailed examination of resource and
organisational differences.
Background
Since devolution in 1999, health policy has increasingly
diverged in the four UK countries (England, Scotland,
Wales and Northern Ireland). [1,2] Health policy across
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the UK continues to share a number of similar objectives
including reducing waiting times, shifting care from hos-
pital to community, reducing health inequalities, and
improving clinical quality for people with long term con-
ditions. [3,4] However, the preferred mechanisms for
delivering these objectives increasingly vary. [5-8] Post-
devolution, England initially focused on centralised per-
formance management, with rewards and sanctions for
trusts that succeeded or failed to achieve centrally set tar-
gets. Latterly, the emphasis has shifted to implementing a
regulated healthcare market built around patient choice
and increased plurality of providers, allied to an increas-
ing role for the private sector within the primary care set-
ting. [5-7] Scotland has abolished the purchaser-provider
split and (re)created vertically integrated Health Boards,
with an emphasis on professionalism and clinical leader-
ship, particularly in managed clinical networks to co-ordi-
nate care across organisational and professional
boundaries. [8] The distinctive feature of Welsh policy is a
strong emphasis on public health, with local health
boards having a duty of partnership with local authorities
in commissioning. [9] In Northern Ireland, political
uncertainty has meant that major organisational reform
has not been implemented. [1]
Therefore a natural experiment is in progress in UK
healthcare, and cross-jurisdictional comparison is of
growing interest. Examining this natural experiment is dif-
ficult because data are often not comparable, partly
because data definitions and collection are not consistent,
even for healthcare expenditure and analysis of National
Health Service (NHS) workforce. [3] Two recent compari-
sons indicate that England has been more successful than
Wales and Northern Ireland in rapidly reducing waiting
times for first outpatient appointment and elective sur-
gery, although these are now also falling in Wales and
Northern Ireland. Though not fully comparable, Scottish
waiting times are consistently lower over the whole period
despite waiting times in England falling faster than in
Scotland between 2002 and 2005. [3,4,10] Other research
has shown that Scotland has higher rates of breast cancer
screening and some immunisations, whereas England has
lower mortality from colorectal cancer and ischaemic
heart disease, and Wales has the highest rate of statin pre-
scribing. [11] There are substantial variations in per-capita
healthcare spending, with England spending the least and
Scotland the most, although at country level, these differ-
ences are partly explained by differences in need, and have
reduced post-devolution due to faster growth in health-
care spending in England. [3] Nonetheless, mean listsize
per whole time equivalent GP remains lower in Scotland
than in other UK countries (partly due to greater rurality).
[12] There is no recent comparable data on practice nurse
and other practice employed staff available at national
levels (Table 1). [13]
The Quality and Outcomes Framework (QOF) of the
2004 General Medical Services contract provides a new
opportunity to compare clinical quality using measures
with consistent definition and data collection in all four
countries. [3,4,14] However, although QOF is designed to
incentivise high quality care and is unique in scale and
scope for a national pay-for-performance program, it is
not comprehensive in its coverage. There remain a wide
variety of measures that can have a significant impact on
the quality of care, which are not included. Nevertheless,
QOF is consistent across all four UK counties and offers
the best current opportunity to compare differences in
clinical quality. QOF data is reported at practice level as
the proportion of eligible patients achieving each indica-
tor, and case-mix adjustment using patient level data is
therefore not possible. However, data reported for pay-
ment (which we call 'payment' quality and others have
called 'reported' quality [22] allows practices to 'exception
report' individual patients for a range of reasons, includ-
ing patient not attending for care, patient dissent, and
patient on maximum treatment. An exception reported
patient is removed from the denominator for each indica-
tor. In principle, exception reporting should therefore
adjust for case-mix variation. For example, in Scotland in
2004/5, there is no consistent socio-economic gradient in
quality using 'payment' quality (which allows excep-
tions), whereas practices serving more deprived popula-
tions have lower 'population' achievement for many
measures (calculation of which does not allow excep-
tions). [15] This paper uses QOF data to compare the
quality of care for diabetes and cardio-vascular disease
(coronary heart disease [CHD], stroke and transient
ischaemic attack, and hypertension) in the four UK coun-
tries. All of these conditions cause considerable morbidity
and mortality, and the relevant QOF measures are under-
pinned by a strong evidence base of guidelines and
National Service Frameworks. [14] Differences in the aver-
age QOF financial incentive in each country are examined
by comparing QOF reported prevalence of incentivised
disease. QOF payment within countries varies by preva-
lence of disease in each practice, but this is compared to
mean prevalence in each country. However, as payment
for the average prevalence practice achieving the same
points total in each country is the same, the average per-
patient rewards for quality are therefore lower in higher
prevalence countries.
Methods
The analysis used publicly available data on QOF achieve-
ment for each practice. [16-19]. Practices with missing
data or those with no patients in their denominators were
excluded, leaving 8,214 (96%) practices in England, 1023
(98%) in Scotland, 362 (99%) in Northern Ireland and
459 (92%) in Wales.BMC Health Services Research 2007, 7:74 http://www.biomedcentral.com/1472-6963/7/74
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The Quality Management and Analysis System (QMAS)
reports quality measures in the form of 'percentage of eli-
gible patients achieving measure', from which practices
are allowed to exception report patients for a variety of
reasons ('payment' quality). Although 'payment quality' is
therefore effectively a crude form of case-mix adjustment,
any differences between countries might reflect differ-
ences in exception reporting as well as differences in
actual quality of care.
Exception reporting rates are not directly available in
QMAS for 2004/5 data, but 'population achievement' (a
measure which does not allow exceptions) can be esti-
mated for measures where the non-excepted denominator
is the number of patients on the disease register. This
method has been outlined in detail elsewhere. [20] In
short, we estimate the register size at 31st March using the
maximum value of any denominator in the relevant clin-
ical domain to calculate exception rates and population
achievement. For the intermediate outcomes measures,
this method assumes that unmeasured patients are
uncontrolled. In the analysis we report 'payment quality'
as the primary outcome, assuming that there is some
adjustment for case-mix, but additionally examine differ-
ences in 'population' achievement as a form of sensitivity
analysis.
Indicators were classified into four groups: simple proc-
ess; complex process; intermediate outcome (e.g. level of
blood pressure achieved); and treatment (e.g. influenza
immunisation). We distinguished simple and complex
processes in terms of whether they could easily be deliv-
ered opportunistically irrespective of whom the patient
was seeing. A simple process is therefore one that can be
delivered during routine care by any doctor or nurse, such
as blood pressure measurement or blood taking. A com-
plex process either requires referral to a specialist such as
diabetic retinal screening, or is likely to be done only by
particular primary care clinicians such as comprehensive
diabetic foot examination. Table 2 details the indicators
used in each category.
A simple composite of the achievement levels by indicator
category was calculated for each country, by adding up the
mean values for each indicator within a particular group
and then dividing by the number of indicators in that
group (e.g. for complex process indicators- average
achievement levels of 70%, 80% and 75% would be
added together and divided by three to give a composite
achievement level of 75%).
Summary statistics and analyses were based on practice-
level data weighted by register size. Since the distributions
of many of the quality indicators are non-normal, we pro-
vide bootstrapped confidence intervals based on 2,000
replications. [21] We use 99% confidence levels in recog-
nition of the large number of comparisons.
Crude prevalence rates for each disease in each country
were calculated for each disease domain by dividing the
total number of patients on practice disease registers by
the total populations registered with practices. The analy-
sis was undertaken in STATA v8.2.
Results
Table 3 shows average payment and population achieve-
ment in each of the four indicator categories by country.
Northern Ireland has the highest achievement under both
payment and population achievement for simple process,
intermediate outcomes and treatment indicators. Scot-
land has the highest achievement for the complex process
indicators. Wales has the lowest achievement for all cate-
gories for both payment and population achievement.
Table 4 shows that the higher achievement levels in
Northern Ireland compared to England are statistically
significant. Scotland has significantly higher achievement
than England for all indicator categories under payment
quality but not for the treatment measures under popula-
tion achievement due to higher exclusion rates. Wales has
significantly lower achievement than England for com-
plex process and treatment indicators for both payment
and population achievement and for outcomes based on
population achievement only.
Table 1: Structural GP and practice characteristics in four UK countries
Variable England Wales Scotland Northern Ireland
Number of practices 8542 501 1056 366
Number of whole-time equivalent (WTE) GPs 31523 1816 3782 1078
Average registered population 6401 6171 5249 5361
Average number of GPs per practice 3.7 3.6 3.6 3.0
Registered population per WTE GP 1666 1674 1343 1663
Single-partner practices (%) 23 19 16 19
Practices with six or more GPs (%) 21 16 20 9
*All figures for 2004-05 with the exception of Northern Ireland 2003-4[12]BMC Health Services Research 2007, 7:74 http://www.biomedcentral.com/1472-6963/7/74
Page 4 of 8
(page number not for citation purposes)
Achievement across the process, intermediate outcome
and treatment indicators is generally highest in Northern
Ireland and lowest in Wales (Tables 5 and 6). Northern
Ireland has significantly higher quality than England for
23 of the 31 indicators and lower quality only for the per-
centage of diabetics with HbA1c < 7.4. Wales has signifi-
cantly lower quality than England for 17 of the 31
indicators. Scotland has significantly higher quality than
England on 19 indicators and significantly lower quality
on 5 indicators.
For simple process measures, like the recording of blood
pressure or smoking status, absolute differences between
the highest and lowest performing countries are generally
small and probably of little clinical significance. Most dif-
ferences are less than 1% and only cholesterol recording
in people with stroke shows a difference greater than 5%
between Northern Ireland and Wales. For the more com-
plex diabetes process measures, such as retinopathy
screening, absolute differences between highest and low-
est performing countries are larger (5–10%) and Scotland
has the highest quality. For intermediate outcome and
treatment indicators, absolute differences are also greater,
and clinically significant. Again, Northern Ireland gener-
ally has the highest quality and Wales the lowest.
Table 7 shows that average prevalence rates vary by up to
28% (the difference in CHD prevalence between England
and Scotland). England has the lowest reported preva-
lence for CHD and stroke, and Northern Ireland for dia-
betes and hypertension. Prevalence rates are highest for
CHD and stroke in Scotland and for diabetes and hyper-
tension in Wales
Discussion
This is the first study to undertake a comparison of quality
of care between the four countries of the UK using QOF
data. The key findings are that the quality of care meas-
Table 2: List of indicators used
Disease area Indicator definition Payment range
Simple process
CHD 03 Record of smoking status in the previous 15 months 25–90%
Stroke 03 Record of smoking status in the previous 15 months 25–90%
Hypertension 03 Record of smoking status since diagnosis 25–90%
Diabetes 03 Record of smoking status in the previous 15 months 25–90%
CHD 05 Record of blood pressure in previous 15 months 25–90%
Stroke 05 Record of blood pressure in previous 15 months 25–90%
Hypertension 04 Record of blood pressure in previous 9 months 25–90%
Diabetes 11 Record of blood pressure in the previous 15 months 25–90%
CHD 07 Record of total cholesterol in previous 15 months 25–90%
Stroke 07 Record of total cholesterol in previous 15 months 25–90%
Diabetes 16 Record of total cholesterol in previous 15 months 25–90%
Diabetes 02 Record of BMI in previous 15 months 25–90%
Diabetes 05 Record of H1Abc or equivalent in previous 15 months 25–90%
Diabetes 14 Record of serum creatinine testing in the previous 15 months 25–90%
Complex Process
Diabetes 08 Record of retinal screening in the previous 15 months 25–90%
Diabetes 09 Record of peripheral pulse test in the previous 15 months 25–90%
Diabetes 10 Record of neuropathy testing in the previous 15 months 25–90%
Outcome
CHD 06 Blood pressure recorded in previous 15 months ≤ 150/90 25–70%
Stroke 06 Blood pressure recorded in previous 15 months ≤ 150/90 25–70%
Hypertension 05 Blood pressure recorded in previous 15 months ≤ 150/90 25–70%
Diabetes 12 Blood pressure recorded in previous 15 months ≤ 145/85 25–55%
CHD 08 Total cholesterol recorded in previous 15 months ≤ 5 mmol/l 25–60%
Stroke 08 Total cholesterol recorded in previous 15 months ≤ 5 mmol/l 25–60%
Diabetes 17 Total cholesterol recorded in previous 15 months ≤ 5 mmol/l 25–60%
Diabetes 06 HbA1c recorded in previous 15 months ≤ 7.4% 25–55%
Diabetes 07 HbA1c recorded in previous 15 months ≤ 10% 25–85%
Treatment
CHD 09 Aspirin, alternative anti-platelet or anti-coagulant being taken 25–90%
CHD 10 Treated with beta-blocker 25–50%
CHD 12 Record of Influenza immunisation in previous flu season 25–85%
Stroke 12 Record of Influenza immunisation in previous flu season 25–85%
Diabetes 12 Record of Influenza immunisation in previous flu season 25–85%BMC Health Services Research 2007, 7:74 http://www.biomedcentral.com/1472-6963/7/74
Page 5 of 8
(page number not for citation purposes)
ured by the QOF is generally highest in Northern Ireland
and lowest in Wales, and that the financial incentive for
quality is proportionately lower in Wales and Scotland.
The strength of the study is that it uses clinical quality data
for important diseases collected to a common definition
for 96% of UK general practices. Although QOF is not a
fully comprehensive quality dataset, it exceeds all previ-
ous cross-jurisdictional comparisons in terms of the scope
and coverage of primary care clinical activity. However,
the analysis is limited by the nature of the data, which
reflects its origin in a payment, rather than a quality mon-
itoring, system. In particular, the data are at practice level,
which makes patient-level case-mix adjustment impossi-
ble. Although exception reporting of patients who are
unsuitable for or who decline care should function as a
crude form of patient level case-mix adjustment, excep-
tion reporting is under practice control, potentially serves
practices' financial self-interests, and could systematically
vary by country. However, the overall conclusions are
unchanged whether examining quality measures that
allow exception reporting or not. Finally, although QOF
data are consistent, other practice level variables are not
(for example, data on practice employed staff) which lim-
its exploration of potential resource or organisational
explanations for the differences that are observed.
Cross-jurisdictional comparisons using routine data are
helpful in identifying broad trends and areas of concern.
QOF adds to existing comparisons because of its focus on
clinical quality, and its near comprehensive coverage.
However, the lack of comparable data on practice
resources and organisation means that it is difficult to
account for the differences seen beyond generating
hypotheses for more detailed examination.
The most notable finding is that quality of CHD, stroke
and diabetes care in Wales on these measures is signifi-
cantly lower than elsewhere in the UK for complex care
processes, intermediate outcomes, and treatments.
Although varying prevalence between countries means
that practices in Wales are, on average, less financially
incentivised for quality under QOF, this seems unlikely to
Table 4: Average achievement by indicator category for England, and differences from England for other countries
Category England (%) Scotland % point difference 
from England (99% CI)
Wales % point difference from 
England (99% CI)
Northern Ireland   % point   difference 
from   England   (99% CI) 
'Payment quality'
Simple (14 measures) 93.4 0.3 (0.1 to 0.5) -0.7 (-0.9 to 0.2) 1.0 (0.6 to 1.4)
Complex (3 measures) 80.4 4.1 (2.1 to 6.0) -5.1 (-6.4 to 3.7) 1.2 (0.7 to 1.8)
Outcome (9 measures) 72.3 2.4 (1.8 to 3.2) -0.3 (-1.1 to 0.1) 4.0 (2.1 to 6.0)
Treatment (5 measures) 82.4 1.0 (0.4 to 1.5) -2.6 (-3.4 to -1.7) 3.0 (2.2 to 3.9)
'Population achievement'
Simple (14 measures) 91.9 0.7 (0.5 to 0.9) -0.2 (-0.5 to 0.1) 1.5 (1.2 to 1.8)
Complex (3 measures) 76.4 2.7 (3.9 to 2.6) -4.5 (-6.0 to -2.9) 1.3 (0.2 to 2.4)
Outcome (9 measures) 68.2 1.6 (0.7 to 2.5) -1.1 (-1.6 to -0.4) 4.0 (3.3 to 4.7)
Treatment (5 measures) 72.6 0.2 (-0.4 to 0.3) -4.3 (5.3 to 3.2) 3.8 (2.8 to 4.7)
Note: Bold type = significant at P < 0.01.
Table 3: Average percentage achievement by indicator category and country
Category England Scotland Wales Northern Ireland
'Payment quality'
Simple (14 measures) 93.4 93.7 92.7 94.4
Complex (3 measures) 80.4 84.5 75.3 81.6
Outcome (9 measures) 72.3 74.7 72.0 76.3
Treatment (5 measures) 82.4 83.4 79.8 85.4
'Population achievement'
Simple (14 measures) 91.9 92.6 91.6 93.4
Complex (3 measures) 76.4 79.1 71.9 77.7
Outcome (9 measures) 68.2 69.8 67.1 72.2
Treatment (5 measures) 72.6 72.8 68.3 76.4BMC Health Services Research 2007, 7:74 http://www.biomedcentral.com/1472-6963/7/74
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Table 6: Average achievement on each outcome and treatment indicator for England and differences from England for other countries 
(99% confidence intervals)
Indicator England (%) Scotland % point 
difference from England 
(99% CI)
Wales % point difference 
from England (99% CI)
Northern Ireland   % 
point   difference from   
England   (99% CI) 
Intermediate outcome
CHD – blood pressure ≤ 150/90 84.1 1.1 (0.4 to 1.8) -0.8 (-2.1 to 0.2) 3.5 (2.7 to 4.4)
Stroke – blood pressure ≤ 150/90 81.0 2.2 (1.2 to 3.1) -2.1 (-3.6 to -0.7) 4.4 (3.2 to 5.4)
Hypertension – BP ≤ 150/90 71.4 0.9 (-0.1 to 1.8) -1.4 (-2.7 to -0.2) 5.0 (3.8 to 6.2)
Diabetes – blood pressure ≤ 145/85 70.4 4.3 (3.3 to 5.2) -2.0 (-3.4 to -0.5) 6.5 (5.4 to 7.8)
CHD – cholesterol ≤ 5 mmol/l 72.2 -1.5 (-2.7 to -0.4) -1.8 (-3.5 to -0.2) -0.4 (-2.2 to 0.4)
Stroke – cholesterol ≤ 5 mmol/l 62.7 2.4 (0.8 to 3.8) -3.7 (-6.1 to -1.4) 2.8 (0.8 to 4.7)
Diabetes – cholesterol ≤ 5 mmol/l 72.0 2.4 (1.4 to 3.4) 0.3 (-1.1 to 1.7) 3.7 (2.5 to 5.0)
Diabetes – HBA1c ≤ 7.4% 59.0 -2.1 (-3.1 to -1.1) -1.6 (-2.7 to -0.4) -2.1 (-3.6 to -0.5)
Diabetes – HBA1c ≤ 10% 89.5 0.6 (0.0 to 1.2) -1.0 (-2.0 to -0.1) 1.1 (0.3 to 1.9)
Treatment
CHD – on aspirin or equivalent 90.2 -0.3 (-0.8 to 0.3) -1.5 (-2.5 to -0.8) 1.7 (0.9 to 2.4)
CHD – on beta-blocker 64.9 4.5 (3.4 to 5.7) -1.8 (-3.4 to -0.2) 6.7 (4.9 to 8.6)
CHD – had influenza vaccination 87.2 -0.4 (-1.4 to 0.6) -3.4 (-5.0 to -1.7) 1.9 (0.6 to 3.2)
Stroke – had influenza vaccination 84.0 0.2 (-0.8 to 1.3) -4.5 (-6.9 to -2.4) 1.5 (-0.7 to 3.0)
Diabetes – had influenza vaccination 74.4 -1.6 (-2.6 to -0.9) -4.3 (-5.6 to -3.0) 3.2 (2.0 to 4.4)
Note: Bold type = significant at P < 0.01
Table 5: Average achievement on each process indicator for England and differences from England for other countries (99% confidence 
intervals)
Indicator England (%) Scotland % point 
difference from England 
(99% CI)
Wales % point 
difference from England 
(99% CI)
Northern Ireland   % 
point   difference from   
England   (99% CI) 
Simple process measures
CHD smoking status recorded 95.0 0.5 (0.1 to 0.9) -0.3 (-1.0 to 0.4) 1.1 (0.4 to 1.7)
Stroke smoking status recorded 92.6 1.5 (0.8 to 2.2) -0.6 (-1.8 to 0.7) 2.0 (1.1 to 3.0)
BP smoking status recorded 94.2 1.2 (0.7 to 1.6) 0.4 (-0.4 to 1.0) 0.7 (0.1 to 1.3)
Diabetes smoking status recorded 96.0 1.4 (1.0 to 1.8) -0.4 (-1.1 to 0.2) 1.3 (0.8 to 1.8)
CHD – blood pressure recorded 96.6 -1.1 (-1.5 to -0.7) -0.2 (-0.7 to 0.2) 0.3 (-0.2 to 0.8)
Stroke – blood pressure recorded 94.9 -0.3 (-0.9 to 2.5) -0.9 (-1.9 to -0.0) 1.0 (0.2 to 1.6)
BP – blood pressure recorded 90.2 -1.3 (-1.9 to -0.7) -0.0 (-0.9 to 0.7) 1.4 (0.5 to 2.3)
Diabetes – blood pressure recorded 97.1 0.6 (0.3 to 0.9) 0.7 (-0.4 to 0.4) 0.9 (0.5 to 1.2)
CHD – cholesterol recorded 90.3 -1.4 (-2.3 to -0.5) -0.7 (-1.9 to 0.4) 1.2 (0.1 to 2.3)
Stroke – cholesterol recorded 84.1 0.9 (-0.3 to 2.3) -2.7 (-4.9 to -0.5) 3.0 (1.1 to 4.7)
Diabetes – cholesterol recorded 92.9 1.5 (0.9 to 2.0) -0.1 (-1.1 to 0.8) 1.8 (1.1 to 2.5)
Diabetes-record of Body Mass Index 90.8 2.9 (2.4 to 3.3) 1.1 (0.4 to 1.8) 1.6 (0.7 to 2.4)
Diabetes-record of HbA1c 94.6 1.6 (1.2 to 2.0) -0.7 (-1.3 to -0.5) 1.8 (1.4 to 2.2)
Diabetes – creatinine recorded 93.2 1.3 (0.4 to 1.9) -0.7 (-1.7 to 0.2) 0.3 (-0.6 to 1.3)
Complex process measures
Diabetes – retinal screening recorded 83.8 2.7 (1.5 to 3.8) -2.9 (-4.9 to -0.7) -0.2 (-2.3 to 0.7)
Diabetes – peripheral pulses recorded 79.4 5.0 (3.6 to 6.3) -4.8 (-7.6 to -2.3) 1.9 (-0.8 to 4.3)
Diabetes – neuropathy testing recorded 78.1 4.6 (3.1 to 6.1) -7.7 (-10.9 to -4.5) 2.0 (-0.6 to 4.3)
Note: Bold type = significant at P < 0.01BMC Health Services Research 2007, 7:74 http://www.biomedcentral.com/1472-6963/7/74
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have directly influenced motivation to deliver high qual-
ity in the first year because the detailed link between per-
formance and reward in the payment system is opaque.
[15] However, in the longer term, lower payment rates per
patient for the same level of quality might be expected to
affect quality. Notably, the measures for which Wales con-
sistently performs poorly are those for which practices are
more likely to require collaboration with larger NHS
organisations (organisation of diabetes care, effective
management of intermediate outcomes, influenza vacci-
nation), rather than simple processes directly under prac-
tice control. The evidence from this study is therefore
consistent with previously identified waiting time prob-
lems being symptomatic of a wider quality problem
within NHS Wales, and requires closer examination.
NHS Scotland has generally higher quality than NHS Eng-
land, particularly on the complex process measures for
diabetes. The largest difference is for diabetic foot exami-
nation. In theory, Scottish policy on the co-ordination of
care for whole populations by managed clinical networks
might be expected to have a beneficial impact on such
indicators. This finding is also consistent with other evi-
dence of higher quality in Scotland for services requiring
area-based co-ordination like immunisation and breast
screening. [11] On average, Scotland has substantially
more whole time equivalent GPs per 1000 registered
patients than England which might also be expected to
lead to higher QOF performance (although the higher
prevalence of cardiovascular disease implies more work
per GP than registered list differences alone imply).
The generally small differences that we have observed may
be reassuring for NHS England, where the focus of targets
and market reform on acute services and elective surgery
does not appear to have seriously affected quality of
chronic disease care, at least for these incentivised meas-
ures. However, the true test of the success of a policy of
increasing market reform and the setting of targets in pri-
mary care will require additional research on how the
introduction of the QOF has impacted on those areas not
covered by the GMS contract.
Finally, it is striking that clinical quality in Northern Ire-
land is higher than in the rest of the UK. This may reflect
greater population or health service stability, for example
because Northern Ireland has experienced less diversion
of management and clinical attention due to repeated re-
organisation. It may also in part be a consequence of
Northern Ireland having a younger population compared
to the UK as a whole with evidence from England suggest-
ing that practices with a higher proportion of over 65 year-
olds have lower achievement. [22]
Conclusion
Previously identified weaknesses in Wales related to wait-
ing times appear to reflect a more general quality problem
within NHS Wales. The introduction of QOF data and this
subsequent analysis adds to the existing relatively sparse
literature on cross-jurisdictional differences in quality of
care within the UK. However, such routine data sets are
predominately useful for identifying overall patterns and
areas for more detailed examination by focused research
projects. Although some research to tease out the impact
of diverging health policy has recently been funded,
[23,24] maximising the potential for cross-jurisdictional
learning within the UK will require more detailed, com-
parative examination of the organisation and resourcing
of primary medical care, and collection of a wider range of
clinical process and outcome measures, including care for
non-incentivised diseases.
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